1. GLENMARK
PHARMACEUTICALS LTD.
By- SURAJ WARTHY
9110
B

2. INTRODUCTION
Founded- in 1977
Founder- Mr. Gracias Saldanha
Headquartered- Mumbai, India
Industry-Pharmaceuticals Drug &Healthcare
Traded as –BSE: 532296 NSE: GLENMARK
Key people-Glenn Saldanha, MD & CEO
Products- Medicines and Vaccines
Revenue- Glen mark's consolidated revenue increases by 18.98% to Rs.
12,378.82 Mn for Q1 FY 13-14
Employees-7,000
Subsidiaries- Glenmark Generics Ltd.

3. GLENMARK‘S BUSINESS INTO TWO CATEGORIES-
SPECIALITY BUSINESS AND GLENMARK GENERICS LTD.
Glenmark branded generics 5 regions Asia including India, Central Eastern Europe, Africa, Latin
America and CIS.
Glenmark has established itself among the top 25 generics companies in the US and also built a
sizeable API business in a short period.
Formulation business, its business spans segments such as-
Dermatology
Internal Medicine
Paediatrics
Gynaecology
ENT and Diabetes.

4. The company's business in Africa and Middle East markets -:
GLENMARK launched new products showing 40 % increase in 2012-13
PRODUCT COUNTRY
Supiroban south Africa
Flexilor Kenya
Glimulin UAE
API segments global generic players-:
The business continues its leadership position for –
Lercandipine Topiramate Amiodarone

5. TOP 5 MAJOR COMPETITORS OF GLENMARK
SUN PHARMA
DR.REDDY’S
LAB
LUPIN CIPLA
GLAXOSMITHKLINE
Glenmark’s current portfolio consists of 83 products authorized for distribution in the U.S. market .
46 ANDA’s pending approval with the U.S. FDA.

6. STRENGTH-
•Extremely productive R&D efforts.
Strong NCE pipeline with three
compounds in Phase II clinical trials.
•Built-up skills in NCE research over
last 6 years.
•Built-up strong franchises in the US
generic market in a short duration.
WEAKNESS-
•Currency appreciation as exp
contributes 55% of Glenmark’s
revenues (excluding license fees)
•Negligible presence in the European
Markets.
OPPORTUNITY-
•Re-negotiation of GRC-8200 with
another partners.
•Focus on Biologics research ~ huge
potential going forward.
•A pipeline of 11 compounds comprising
of 6 NCEs and 5 NBEs.
THREATS-
•Risk of failure/ delays in NCE research.
•Acquisition and integration risk.
•Pricing pressure in the regulated
generic markets.
•Execution risk in the base business.

7. STRATEGY
TARGET 2015
“Global end-to-end Specialty Company”
Product Portfolio
Launch two proprietary drugs
Build late stage pipeline
Market Presence
Proprietary product front ends in US, key ROW & European markets
Market Positioning
Innovation led company
Differentiated branded generic company

8. GROWTH STRATEGIES TO BRIDGE GAP-
Licensing
Build differentiated product franchise
Invest in building brands
Expand into new territories
Transition into a proprietary product marketing company

9. Particulars % holdings
Promoters 48.27
FIIs 34.92
Indian Financial Inst., Banks, 3.35
Bodies Corporate 1.76
Mutual Funds 1.12
Non Resident Indians 0.56
Resident Individuals 9.28
Others 0.74
Total 100.00
Shareholding Pattern (As on 31-03-2013):
MERGER WITH MOTILAL OSWAL
•Investors are recommended to buy the stock for a price
target of Rs565 for medium to long term investment.

10. CSR ACTIVITIES
CHILD HEALTH:
•Niramaya Health Foundation, Mumbai
(www.niramaya.org), Spandan Samaj Sewa
Samiti, Khandwa, Madhya Pradesh
SUSTAINABLE LIVELIHOOD:
•sustainable livelihood through Skill development courses in Nasik.
•Individuals who are disabled are rehabilitated thereby enabling them
to lead productive lives, through Jaipur Foot a renowned NGO.
Employee Volunteering & Medicine donation:
•around 1900 employees have offered their support, time and help for
various initiatives. Medicine donation, medical camps, ambulatory

11. CONCLUSION:
SPECIALITY FORMULATIONS BUSINESS
REVENUE, EXCLUDING OUT-LICENSING,
GREW BY 20.37 % TO RS. 607.41 CR FOR THE QUARTER ENDED JUNE
30, 2013 FROM RS. 504.64 CR FOR THE CORRESPONDING PERIOD
PREVIOUS FISCAL.
THE COMPANY'S GENERICS BUSINESS ,GREW TO RS. 624.25
CRORE FROM RS.530 CRORE, A GROWTH OF 17.78 % WITH US
GENERICS BUSINESS GROWING BY 13.91 %....
LOOKING INTO THE PRESENT SCENARIO OF THIS PRODUCT INTO THE
MARKET. THE POSITION OF THIS PRODUCT IN THE MEDIUM ,IT IS NOT IN THE
VERY GOOD POSITION BUT IT HAS THE SCOPE OF BEING IN A BETTER
POSITION. THIS COMPANY WILL SURELY ACHIEVED ITS DESIRED OBJECTIVES
VISION MISSIONS AND TARGETS ,WILL BE IN THE TOP POSITION OF
PHARMACEUTICAL MARKET